Article
HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.
Antiviral therapy - 1 Jan 2017
Gozlan Yael, Ben-Ari Ziv, Moscona Roy, Shirazi Rachel, Rakovsky Aviya, Kabat Arij, Veizman Ella, Berdichevski Tania, Weiss Peretz, Cohen-Ezra Oranit, Lurie Yoav, Gafanovich Inna, Braun Marius, Cohen-Naftaly Michal, Shlomai Amir, Shibolet Oren, Zigmond Ehud, Zuckerman Eli, Carmiel-Haggai Michal, Nimer Assy, Hazzan Rawi, Maor Yaakov, Kitay-Cohen Yona, Shemer-Avni Yonat, Kra-Oz Zipi, Schreiber Licita, Peleg Ofer, Sierra Saleta, Harrigan P Richard, Mendelson Ella, Mor Orna
Abstract excerpt
BACKGROUND: Direct-acting antiviral (DAA) treatment regimens and response rates of patients with HCV genotype-1 (GT1) are currently considered subtype-dependent. Identification of clinically relevant resistance-associated substitutions (RASs) in the NS3 and NS5A proteins at baseline and in DAA failures, may also impact clinical decisions. METHODS: In a multicentre cohort study (n=308), NS3 or NS5B sequencing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.